<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2221-2450</journal-id>
<journal-title><![CDATA[Revista CENIC Ciencias Biológicas]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. CENIC Cienc. Biol]]></abbrev-journal-title>
<issn>2221-2450</issn>
<publisher>
<publisher-name><![CDATA[Centro Nacional de Investigaciones Científicas]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2221-24502023000100095</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[ANTIMICROBIANOS DE ÚLTIMA GENERACIÓN]]></article-title>
<article-title xml:lang="en"><![CDATA[STATE-OF-THE-ART ANTIMICROBIALS]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Campaña Burguet]]></surname>
<given-names><![CDATA[Allelen]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad de Logroño  ]]></institution>
<addr-line><![CDATA[ La Rioja]]></addr-line>
<country>España</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>00</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>00</month>
<year>2023</year>
</pub-date>
<volume>54</volume>
<fpage>95</fpage>
<lpage>101</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S2221-24502023000100095&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S2221-24502023000100095&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S2221-24502023000100095&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN En la actualidad, una de las prioridades de la Organización Mundial de la Salud son las bacterias resistentes a los antibióticos. Las bacterias tienen una gran capacidad de diseminación y dificultan el tratamiento de enfermedades infecciosas, es conocido que poseen una alta morbilidad y mortalidad a nivel mundial, lo que se considera una problemática de salud pública global. El objetivo es realizar una revisión documental de antimicrobianos de última generación, que pueden constituir una alternativa terapéutica. Se realizó un análisis de la información disponible y documentada en la literatura científica consultada. El muestreo se realizó entre los años 2015-2022, para abarcar los últimos años. Se utilizó como herramienta de la infotecnología los buscadores Google académico, PubMed y MDPI. En la actualidad existen nuevas alternativas de antibióticos entre los que se encuentran Ceftolozano-tazobactam, Ceftazidima-avibactam, Ceftarolina, Ceftobiprol, Dalbavancina, Telavancina, Tedizolid, Omadaciclina, Delafloxacina y Lefamulina. También, se corroboró el uso de péptidos que presentan actividad frente a infecciones bacterianas, por hongos o víricas, así como de bacteriófagos que diferentes estudios han demostrado la eficacia de la fagoterapia frente a infecciones. En los últimos años, la comunidad científica ha sido atraída por la llamada terapia fototérmica para combatir patógenos (nanomateriales y metales), los antimicrobianos derivados de plantas y otros avances como las bifosfocinas y los hidrogeles que puedan ser utilizadas en el tratamiento de infecciones causadas por bacterias resistentes a los antibióticos. Se concluye que existen antimicrobianos de última generación que podrían formar parte, ahora o en el futuro, de un nuevo arsenal terapéutico.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT Currently, one of the priorities of the World Health Organization is antibiotic-resistant bacteria. Bacteria have a great capacity for dissemination and make it difficult to treat infectious diseases. It is known that they have high morbidity and mortality worldwide, which is considered a global public health problem. The objective is to carry out a documentary review of the latest generation antimicrobials, which may constitute a therapeutic alternative. An analysis of the information available and documented in the scientific literature consulted was carried out. The sampling was carried out between the years 2015-2022, to cover the last years. Google academic, PubMed and MDPI search engines were used as an infotechnology tool. At present there are new antibiotic alternatives among which are Ceftolozano-tazobactam, Ceftazidime-avibactam, Ceftaroline, Ceftobiprole, Dalbavancin, Telavancin, Tedizolid, Omadacycline, Delafloxacin and Lefamulin. Also, the use of peptides that have activity against bacterial, fungal or viral infections was confirmed, as well as bacteriophages that different studies have shown the efficacy of phage therapy against infections. In recent years, the scientific community has been attracted by the so-called photothermal therapy to combat pathogens (nanomaterials and metals), plant-derived antimicrobials and other advances such as bisphocins and hydrogels that can be used in the treatment of infections caused by antibiotic resistant bacteria. It is concluded that there are state-of-the-art antimicrobials that could be part, now or in the future, of a new therapeutic arsenal.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[antimicrobianos]]></kwd>
<kwd lng="es"><![CDATA[bacterias resistentes]]></kwd>
<kwd lng="es"><![CDATA[nuevos fármacos]]></kwd>
<kwd lng="en"><![CDATA[antimicrobials]]></kwd>
<kwd lng="en"><![CDATA[resistant bacteria]]></kwd>
<kwd lng="en"><![CDATA[new drugs]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="">
<collab>Agencia Española de Medicamentos y Productos Sanitarios (AEMPS)</collab>
<source><![CDATA[La cooperación entre investigadores, administración y empresas, clave para ofrecer nuevas alternativas terapéuticas frente a la resistencia a los antimicrobianos]]></source>
<year>2018</year>
</nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="">
<collab>Naciones Unidas</collab>
<source><![CDATA[La OMS alerta de que el desarrollo de nuevos antibióticos está &#8220;estancado&#8221;]]></source>
<year>2022</year>
</nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bassetti]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Pecori]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[Cojutti]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical and pharmacokinetic drug evaluation of delafoxacin for the treatment of acute bacterial skin and skin structure infections]]></article-title>
<source><![CDATA[Expert Opin Drug Metab Toxicol]]></source>
<year>2017</year>
<volume>13</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1193-200</page-range></nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Boparai]]></surname>
<given-names><![CDATA[J.K]]></given-names>
</name>
<name>
<surname><![CDATA[Sharma]]></surname>
<given-names><![CDATA[P.K.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mini Review on Antimicrobial Peptides, Sources, Mechanism and Recent Applications]]></article-title>
<source><![CDATA[Protein &amp; Peptide Letters]]></source>
<year>2020</year>
<volume>27</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>4-16</page-range></nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Das]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
<name>
<surname><![CDATA[Sarkar]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Das]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[Gupta]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Kalra]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Sahni]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Telavancin: a novel semisynthetic lipoglycopeptide agent to counter the challenge of resistant Gram-positive pathogens]]></article-title>
<source><![CDATA[Ther Adv Infectious Dis]]></source>
<year>2017</year>
<volume>4</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>49-73</page-range></nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Davies]]></surname>
<given-names><![CDATA[J. E.]]></given-names>
</name>
<name>
<surname><![CDATA[Behroozian]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[An ancient solution to a modern problem]]></article-title>
<source><![CDATA[Mol. Microbiol]]></source>
<year>2020</year>
<volume>113</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>546-9</page-range></nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Escolà-Vergé]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Los-Arcos]]></surname>
<given-names><![CDATA[I.]]></given-names>
</name>
<name>
<surname><![CDATA[Almirante]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Nuevos antibióticos para el tratamiento de infecciones por microorganismos multirresistentes]]></article-title>
<source><![CDATA[Med Clin (Barc)]]></source>
<year>2020</year>
<volume>154</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>351-7</page-range></nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gallagher]]></surname>
<given-names><![CDATA[J. C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Omadacycline: A Modernized Tetracycline. Clinical infectious diseases]]></article-title>
<source><![CDATA[Infectious Diseases Society of America]]></source>
<year>2019</year>
<volume>69</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-5</page-range></nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Giacobbe]]></surname>
<given-names><![CDATA[D. R.]]></given-names>
</name>
<name>
<surname><![CDATA[De Rosa]]></surname>
<given-names><![CDATA[F. G.]]></given-names>
</name>
<name>
<surname><![CDATA[Del Bono]]></surname>
<given-names><![CDATA[V.]]></given-names>
</name>
<name>
<surname><![CDATA[Grossi]]></surname>
<given-names><![CDATA[P.A.]]></given-names>
</name>
<name>
<surname><![CDATA[Pea]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
<name>
<surname><![CDATA[Petrosillo]]></surname>
<given-names><![CDATA[N.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ceftobiprole: drug evaluation and place in therapy]]></article-title>
<source><![CDATA[Expert Rev Anti Infect]]></source>
<year>2019</year>
<volume>17</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>689-98</page-range></nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gil-Romero]]></surname>
<given-names><![CDATA[Y.]]></given-names>
</name>
<name>
<surname><![CDATA[Gómez-Garcés]]></surname>
<given-names><![CDATA[J. L.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Actividad in vitro de la combinación de ceftarolina con otros antimicrobianos activos frente a Staphylococcus spp]]></article-title>
<source><![CDATA[Enferm Infecc Microbiol Clin]]></source>
<year>2020</year>
<volume>38</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>25-7</page-range></nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Guevara]]></surname>
<given-names><![CDATA[F. A.]]></given-names>
</name>
<name>
<surname><![CDATA[Muñoz]]></surname>
<given-names><![CDATA[L. C.]]></given-names>
</name>
<name>
<surname><![CDATA[Navarrette]]></surname>
<given-names><![CDATA[J. Salazar]]></given-names>
</name>
<name>
<surname><![CDATA[L. M. Pinilla]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Innovaciones en la terapia antimicrobiana]]></article-title>
<source><![CDATA[Nova]]></source>
<year>2021</year>
<volume>18</volume>
<numero>34</numero>
<issue>34</issue>
<page-range>9:25</page-range></nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hemeg]]></surname>
<given-names><![CDATA[H. A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Nanomaterials for alternative antibacterial therapy]]></article-title>
<source><![CDATA[Int J Nanomedicine]]></source>
<year>2017</year>
<volume>12</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>8211-25</page-range></nlm-citation>
</ref>
<ref id="B13">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jaumaux]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
<name>
<surname><![CDATA[Gómez de Cadiñanos]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Gabant]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[In the Age of Synthetic Biology, Will Antimicrobial Peptides be the Next Generation of Antibiotics?]]></article-title>
<source><![CDATA[Antibiotics]]></source>
<year>2020</year>
<volume>9</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>484</page-range></nlm-citation>
</ref>
<ref id="B14">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kaur]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
<name>
<surname><![CDATA[Reddy]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Barathe]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Shriram]]></surname>
<given-names><![CDATA[V.]]></given-names>
</name>
<name>
<surname><![CDATA[Anand]]></surname>
<given-names><![CDATA[U.]]></given-names>
</name>
<name>
<surname><![CDATA[Pro&#263;ków]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Kumar]]></surname>
<given-names><![CDATA[V.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Combating Drug-Resistant Bacteria Using Photothermally Active Nanomaterials: A Perspective Review]]></article-title>
<source><![CDATA[Front Microbiol]]></source>
<year>2021</year>
<volume>12</volume>
<numero>747019</numero>
<issue>747019</issue>
</nlm-citation>
</ref>
<ref id="B15">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Khare]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
<name>
<surname><![CDATA[Anand]]></surname>
<given-names><![CDATA[U.]]></given-names>
</name>
<name>
<surname><![CDATA[Dey]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Assaraf]]></surname>
<given-names><![CDATA[Y. G.]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[Z. S.]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[Z.]]></given-names>
</name>
<name>
<surname><![CDATA[Kumar]]></surname>
<given-names><![CDATA[V.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Exploring Phytochemicals for Combating Antibiotic Resistance in Microbial Pathogens]]></article-title>
<source><![CDATA[Front Pharmacol]]></source>
<year>2021</year>
<volume>12</volume>
<numero>720726</numero>
<issue>720726</issue>
</nlm-citation>
</ref>
<ref id="B16">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Koulenti]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[Xu]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
<name>
<surname><![CDATA[Sum Mok]]></surname>
<given-names><![CDATA[I. Y.]]></given-names>
</name>
<name>
<surname><![CDATA[Song]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Karageorgopoulos]]></surname>
<given-names><![CDATA[D. E.]]></given-names>
</name>
<name>
<surname><![CDATA[Armaganidis]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Lipman]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Tsiodras]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Novel Antibiotics for Multidrug-Resistant Gram-Positive Microorganisms]]></article-title>
<source><![CDATA[Microorganisms]]></source>
<year>2019</year>
<volume>7</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>270</page-range></nlm-citation>
</ref>
<ref id="B17">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lampejo]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dalbavancin and telavancin in the treatment of infective endocarditis: a literature review]]></article-title>
<source><![CDATA[International Journal of Antimicrobial Agents]]></source>
<year>2020</year>
<volume>56</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>106072</page-range></nlm-citation>
</ref>
<ref id="B18">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lopardo]]></surname>
<given-names><![CDATA[H. A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Fagoterapia: la multirresistencia nos obliga a revisar el pasado]]></article-title>
<source><![CDATA[Rev Argent Microbiol]]></source>
<year>2017</year>
<volume>49</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-2</page-range></nlm-citation>
</ref>
<ref id="B19">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mahlapuu]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Håkansson]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Ringstad]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Björn]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Antimicrobial Peptides: An Emerging Category of Therapeutic Agents. Front. Cell]]></article-title>
<source><![CDATA[Infect. Microbiol]]></source>
<year>2016</year>
<volume>6</volume>
<page-range>194</page-range></nlm-citation>
</ref>
<ref id="B20">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Martínez-Miranda]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Gastélum-Acosta]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Guerrero-Estrada]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Ayala-Figueroa]]></surname>
<given-names><![CDATA[R. I.]]></given-names>
</name>
<name>
<surname><![CDATA[Osuna-Álvarez]]></surname>
<given-names><![CDATA[L. E.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ceftolozane/tazobactam and ceftazidime/avibactam antimicrobial activity against clinically relevant gram-negative bacilli isolated in Mexico]]></article-title>
<source><![CDATA[Gac Med Mex]]></source>
<year>2020</year>
<volume>156</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>592-7</page-range></nlm-citation>
</ref>
<ref id="B21">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nainu]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
<name>
<surname><![CDATA[Permana]]></surname>
<given-names><![CDATA[A. D.]]></given-names>
</name>
<name>
<surname><![CDATA[Djide]]></surname>
<given-names><![CDATA[N. J. N.]]></given-names>
</name>
<name>
<surname><![CDATA[Anjani]]></surname>
<given-names><![CDATA[Q. K.]]></given-names>
</name>
<name>
<surname><![CDATA[Utami]]></surname>
<given-names><![CDATA[R. N.]]></given-names>
</name>
<name>
<surname><![CDATA[Rumata]]></surname>
<given-names><![CDATA[N. R.]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Emran]]></surname>
<given-names><![CDATA[T. B.]]></given-names>
</name>
<name>
<surname><![CDATA[Simal-Gandara]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pharmaceutical Approaches on Antimicrobial Resistance: Prospects and Challenges]]></article-title>
<source><![CDATA[Antibiotics]]></source>
<year>2021</year>
<volume>10</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>981</page-range></nlm-citation>
</ref>
<ref id="B22">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nakatsuji]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[T. H.]]></given-names>
</name>
<name>
<surname><![CDATA[Narala]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Chun]]></surname>
<given-names><![CDATA[K. A.]]></given-names>
</name>
<name>
<surname><![CDATA[Two]]></surname>
<given-names><![CDATA[A. M.]]></given-names>
</name>
<name>
<surname><![CDATA[Yun]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Antimicrobials from human skin commensal bacteria protect against Staphylococcus aureus and are deficient in atopic dermatitis]]></article-title>
<source><![CDATA[Sci Transl Med]]></source>
<year>2017</year>
<volume>9</volume>
<numero>378</numero>
<issue>378</issue>
</nlm-citation>
</ref>
<ref id="B23">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Obed]]></surname>
<given-names><![CDATA[M. N.]]></given-names>
</name>
<name>
<surname><![CDATA[Toresani]]></surname>
<given-names><![CDATA[I.]]></given-names>
</name>
<name>
<surname><![CDATA[Mykietuk]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Nannini]]></surname>
<given-names><![CDATA[E. C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ceftaroline as salvage therapy for methicillin susceptible Staphylococcus aureus complicated bacteremia]]></article-title>
<source><![CDATA[Medicina]]></source>
<year>2022</year>
<volume>82</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>794-7</page-range></nlm-citation>
</ref>
<ref id="B24">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Olascoaga-Del Angel]]></surname>
<given-names><![CDATA[K. S.]]></given-names>
</name>
<name>
<surname><![CDATA[Sánchez-Evangelista]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Carmona-Navarrete]]></surname>
<given-names><![CDATA[I.]]></given-names>
</name>
<name>
<surname><![CDATA[Galicia-Sánchez]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Gómez-Luna]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Islas-Arrollo]]></surname>
<given-names><![CDATA[S. J.]]></given-names>
</name>
<name>
<surname><![CDATA[Castañeda-Sánchez]]></surname>
<given-names><![CDATA[J. I.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Antimicrobial peptides, a promising alternative for the treatment of infectious diseases]]></article-title>
<source><![CDATA[Gac Med Mex]]></source>
<year>2018</year>
<volume>154</volume>
<page-range>582-8</page-range></nlm-citation>
</ref>
<ref id="B25">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Polash]]></surname>
<given-names><![CDATA[S. A.]]></given-names>
</name>
<name>
<surname><![CDATA[Khare]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
<name>
<surname><![CDATA[Kumar]]></surname>
<given-names><![CDATA[V.]]></given-names>
</name>
<name>
<surname><![CDATA[Shukla]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prospects of Exploring the Metal-Organic Framework for Combating Antimicrobial Resistance]]></article-title>
<source><![CDATA[ACS Appl Bio Mater]]></source>
<year>2021</year>
<volume>4</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>8060-79</page-range></nlm-citation>
</ref>
<ref id="B26">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pragya]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
<name>
<surname><![CDATA[Tushar]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
<name>
<surname><![CDATA[Varsha]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Hanhong]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
<name>
<surname><![CDATA[Vinay]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
<name>
<surname><![CDATA[Principi]]></surname>
<given-names><![CDATA[N.]]></given-names>
</name>
<name>
<surname><![CDATA[Silvestri]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
<name>
<surname><![CDATA[Esposito]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Advantages and limitations of bacteriophages for the treatment of bacterial infections]]></article-title>
<source><![CDATA[Front. Pharmacol]]></source>
<year>2019</year>
<volume>10</volume>
<page-range>513</page-range></nlm-citation>
</ref>
<ref id="B27">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Reina]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Reina]]></surname>
<given-names><![CDATA[N.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Fagoterapia ¿una alternativa a la antibioticoterapia? [Phage therapy, an alternative to antibiotic therapy?)]]]></article-title>
<source><![CDATA[Rev Esp Quimioter]]></source>
<year>2018</year>
<volume>31</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>101-4</page-range></nlm-citation>
</ref>
<ref id="B28">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Romero-Calle]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[Benevides]]></surname>
<given-names><![CDATA[R. G.]]></given-names>
</name>
<name>
<surname><![CDATA[Góes-Neto]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Billington]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Bacteriophages as alternatives to antibiotics in clinical care]]></article-title>
<source><![CDATA[Antibiotics]]></source>
<year>2019</year>
<volume>8</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>138</page-range></nlm-citation>
</ref>
<ref id="B29">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Salavert- Lletí]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[García-Bustos]]></surname>
<given-names><![CDATA[V.]]></given-names>
</name>
<name>
<surname><![CDATA[Morata Ruiz]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Cabañero-Navalon]]></surname>
<given-names><![CDATA[M. D.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tedizolid: new data and experiences for clinical practice. Publicación oficial de la Sociedad Española de Quimioterapia]]></article-title>
<source><![CDATA[Revista Española de Quimioterapia]]></source>
<year>2021</year>
<volume>34</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>22-5</page-range></nlm-citation>
</ref>
<ref id="B30">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Scott]]></surname>
<given-names><![CDATA[L. J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Delafloxacin: A Review in Acute Bacterial Skin and Skin Structure Infections]]></article-title>
<source><![CDATA[Drugs. Aug]]></source>
<year>2020</year>
<volume>80</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1247-58</page-range></nlm-citation>
</ref>
<ref id="B31">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sheng]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Tan]]></surname>
<given-names><![CDATA[X.]]></given-names>
</name>
<name>
<surname><![CDATA[Huang]]></surname>
<given-names><![CDATA[Q.]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
<name>
<surname><![CDATA[Zhou]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Guo]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Antibacterial and Angiogenic Poly (ionic liquid) Hydrogels]]></article-title>
<source><![CDATA[Gels]]></source>
<year>2022</year>
<volume>28</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>476</page-range></nlm-citation>
</ref>
<ref id="B32">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shriram]]></surname>
<given-names><![CDATA[V.]]></given-names>
</name>
<name>
<surname><![CDATA[Khare]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
<name>
<surname><![CDATA[Bhagwat]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Shukla]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Kumar]]></surname>
<given-names><![CDATA[V.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Bacterial Drug Efflux Pumps via Phyto-Therapeutics to Combat Threatening Antimicrobial Resistance]]></article-title>
<source><![CDATA[Front Microbiol]]></source>
<year>2018</year>
<volume>9</volume>
<page-range>2990</page-range></nlm-citation>
</ref>
<ref id="B33">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tanaka]]></surname>
<given-names><![CDATA[S. K.]]></given-names>
</name>
<name>
<surname><![CDATA[Steenbergen]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Villano]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic]]></article-title>
<source><![CDATA[Bioorganic &amp; medicinal chemistry]]></source>
<year>2016</year>
<volume>24</volume>
<numero>24</numero>
<issue>24</issue>
<page-range>6409-19</page-range></nlm-citation>
</ref>
<ref id="B34">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tang]]></surname>
<given-names><![CDATA[H. J.]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[J. H.]]></given-names>
</name>
<name>
<surname><![CDATA[Lai]]></surname>
<given-names><![CDATA[C. C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Lefamulin vs moxifloxacin for community-acquired bacterial pneumonia]]></article-title>
<source><![CDATA[Medicine]]></source>
<year>2020</year>
<volume>99</volume>
<numero>29</numero>
<issue>29</issue>
</nlm-citation>
</ref>
<ref id="B35">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Waglechner]]></surname>
<given-names><![CDATA[N.]]></given-names>
</name>
<name>
<surname><![CDATA[Wright]]></surname>
<given-names><![CDATA[G. D.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Antibiotic resistance: It&#8217;s bad, but why isn&#8217;t it worse?]]></article-title>
<source><![CDATA[BMC Biol]]></source>
<year>2017</year>
<volume>15</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>84</page-range></nlm-citation>
</ref>
<ref id="B36">
<nlm-citation citation-type="">
<collab>WHO</collab>
<source><![CDATA[The burden of health care-associated infection worldwide]]></source>
<year>2016</year>
</nlm-citation>
</ref>
<ref id="B37">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Williams]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Plant synthetic biology for producing potent phyto-antimicrobials to combat antimicrobial resistance]]></article-title>
<source><![CDATA[Biotechnology Advances]]></source>
<year>2021</year>
<numero>107729</numero>
<issue>107729</issue>
</nlm-citation>
</ref>
<ref id="B38">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wong]]></surname>
<given-names><![CDATA[J. P.]]></given-names>
</name>
<name>
<surname><![CDATA[DiTullio]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Parkinson]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Bisphosphocins: novel antimicrobials for enhanced killing of drug-resistant and biofilm-forming bacteria]]></article-title>
<source><![CDATA[Future Microbiol]]></source>
<year>2015</year>
<volume>10</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1751-8</page-range></nlm-citation>
</ref>
<ref id="B39">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhanel]]></surname>
<given-names><![CDATA[G. G.]]></given-names>
</name>
<name>
<surname><![CDATA[Love]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Adam]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
<name>
<surname><![CDATA[Golden]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Zelenitsky]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Schweizer]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens]]></article-title>
<source><![CDATA[Drugs]]></source>
<year>2015</year>
<volume>75</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>253-70</page-range></nlm-citation>
</ref>
<ref id="B40">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhanel]]></surname>
<given-names><![CDATA[G. G.]]></given-names>
</name>
<name>
<surname><![CDATA[Esquivel]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Zelenitsky]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Lawrence]]></surname>
<given-names><![CDATA[C. K.]]></given-names>
</name>
<name>
<surname><![CDATA[Adam]]></surname>
<given-names><![CDATA[H. J.]]></given-names>
</name>
<name>
<surname><![CDATA[Golden]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Lynch JP 3rd, Karlowsky JA. Omadacycline: A Novel Oral and Intravenous Aminomethylcycline Antibiotic Agent]]></article-title>
<source><![CDATA[Drugs]]></source>
<year>2020</year>
<volume>80</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>285-313</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
